Zoekresultaten - Birgitta Benda

  • Toon 1 - 4 resultaten van 4
Verfijn jouw resultaten
  1. 1
    Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance

    Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance door Lars Erik Kristensen, Silvio Danese, Arne Yndestad, Cunshan Wang, Edward Nagy, Irene Modesto, Jose L. Rivas, Birgitta Benda

    Gepubliceerd in 2023
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  2. 2
    Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme

    Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme door Jeffrey R. Curtis, Eun Bong Lee, Irina V Kaplan, Kenneth Kwok, Jamie Geier, Birgitta Benda, Koshika Soma, Lisy Wang, Richard J. Riese

    Gepubliceerd in 2015
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  3. 3
    Analysis of Infections and All‐Cause Mortality in Phase II, Phase III, and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

    Analysis of Infections and All‐Cause Mortality in Phase II, Phase III, and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis door Stanley Cohen, S. Radominski, Juan J. Gómez‐Reino, Lisy Wang, Sriram Krishnaswami, Susan P. Wood, Koshika Soma, Chudi Nduaka, Kenneth Kwok, Hernán Valdez, Birgitta Benda, Richard J. Riese

    Gepubliceerd in 2014
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  4. 4
    Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies

    Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies door J. Wollenhaupt, Joel C. Silverfield, Eun Bong Lee, Jeffrey R. Curtis, Susan P. Wood, Koshika Soma, Chudy I. Nduaka, Birgitta Benda, David Gruben, Hiroyuki Nakamura, Yoshihiro Komuro, Samuel H. Zwillich, Lisy Wang, Richard J. Riese

    Gepubliceerd in 2014
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:

Zoekinstrumenten: